A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

Ipilimumab: controversies in its development, utility and autoimmune adverse events

(2009) Jeffrey Weber   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

(2009) J. Weber et al.   CLINICAL CANCER RESEARCH

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Current systemic therapy for metastatic melanoma

(2009) Sanjiv S Agarwala   Expert Review of Anticancer Therapy

Tumor Immunotherapy in Melanoma

(2008) Maya Zigler et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment

(2008) Lawrence Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

(2008) Edward L. Korn et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma

(2008) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY